Roche Xeloda Contraindicated For Patients With Severe Renal Impairment
Executive Summary
Roche's breast cancer treatment Xeloda will carry a contraindication for use in patients with severe renal impairment following a clinical pharmacology study and a subsequent analysis of the clinical safety database.
You may also be interested in...
Roche Xeloda Colorectal Use Clears FDA; Promotions Must Cite Camptosar
Roche will study Xeloda in combination with Pharmacia's Camptosar in colorectal cancer patients following FDA approval of Xeloda April 30 for use in metastatic colorectal cancer patients.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011